Literature DB >> 12553563

CTLA4 gene and autoimmune endocrinopathies: a new marker?

F Pociot1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12553563     DOI： 10.1007/BF03344076

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  17 in total

1.  ICOS is essential for effective T-helper-cell responses.

Authors:  A Tafuri; A Shahinian; F Bladt; S K Yoshinaga; M Jordana; A Wakeham; L M Boucher; D Bouchard; V S Chan; G Duncan; B Odermatt; A Ho; A Itie; T Horan; J S Whoriskey; T Pawson; J M Penninger; P S Ohashi; T W Mak
Journal:  Nature       Date:  2001-01-04       Impact factor: 49.962

2.  ICOS co-stimulatory receptor is essential for T-cell activation and function.

Authors:  C Dong; A E Juedes; U A Temann; S Shresta; J P Allison; N H Ruddle; R A Flavell
Journal:  Nature       Date:  2001-01-04       Impact factor: 49.962

3.  IDDM12 (CTLA4) on 2q33 and IDDM13 on 2q34 in genetic susceptibility to type 1 diabetes (insulin-dependent).

Authors:  Z M Larsen; O P Kristiansen; E Mato; J Johannesen; M Puig-Domingo; A de Leiva; J Nerup; F Pociot
Journal:  Autoimmunity       Date:  1999       Impact factor: 2.815

4.  CTLA-4/CD 28 region polymorphisms in children from families with autoimmune hepatitis.

Authors:  I Djilali-Saiah; P Ouellette; S Caillat-Zucman; D Debray; J I Kohn; F Alvarez
Journal:  Hum Immunol       Date:  2001-12       Impact factor: 2.850

5.  An Mse I RFLP in the human CTLA4 promotor.

Authors:  K Deichmann; A Heinzmann; E Brüggenolte; J Forster; J Kuehr
Journal:  Biochem Biophys Res Commun       Date:  1996-08-23       Impact factor: 3.575

6.  A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation.

Authors:  G Shaw; R Kamen
Journal:  Cell       Date:  1986-08-29       Impact factor: 41.582

7.  Dinucleotide repeat expansion in the CTLA-4 gene leads to T cell hyper-reactivity via the CD28 pathway in myasthenia gravis.

Authors:  D Huang; R Giscombe; Y Zhou; R Pirskanen; A K Lefvert
Journal:  J Neuroimmunol       Date:  2000-06-01       Impact factor: 3.478

8.  CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease.

Authors:  T Kouki; Y Sawai; C A Gardine; M E Fisfalen; M L Alegre; L J DeGroot
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

9.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

10.  The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry.

Authors:  L Nisticò; R Buzzetti; L E Pritchard; B Van der Auwera; C Giovannini; E Bosi; M T Larrad; M S Rios; C C Chow; C S Cockram; K Jacobs; C Mijovic; S C Bain; A H Barnett; C L Vandewalle; F Schuit; F K Gorus; R Tosi; P Pozzilli; J A Todd
Journal:  Hum Mol Genet       Date:  1996-07       Impact factor: 6.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.